{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-225858","form_type":"8-K","ticker":"CATX","cik":"0000728387","company_name":"Perspective Therapeutics, Inc.","filed_at":"2025-10-01T23:59:59+00:00","discovered_at":"2026-05-14T18:02:42.027141+00:00","generated_at":"2026-05-17T05:10:21.744836+00:00","sec_items":["8.01","9.01"],"event_type":"other","sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"confidence":"low","headline":"Perspective Therapeutics files routine corporate presentation update; no material new disclosure","bullets":["Presentation shows [212Pb]VMT-α-NET Phase 1/2a data in NET with confirmed partial response in patient 103-105.","Tolerability data: mild, transient creatinine increase; no unexpected safety signals.","Pipeline includes [212Pb]VMT01 for melanoma and [212Pb]PSV359 targeting FAP-α in trials.","Pre-targeting platform and supply chain manufacturing infrastructure also highlighted."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-225858","json":"https://secwatch.observer/filing/0001193125-25-225858.json","markdown":"https://secwatch.observer/filing/0001193125-25-225858.md","text":"https://secwatch.observer/filing/0001193125-25-225858.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/728387/000119312525225858/0001193125-25-225858-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/728387/000119312525225858/catx-20251001.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T05:10:21.744836+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}